

Generic Name: Diazepam Nasal Spray

Therapeutic Class or Brand Name: Valtoco[®]

Applicable Drugs (if Therapeutic Class): N/A

GPI Code: 721000300009 – Single spray;
7210003000C4 – Pack of two sprays

Preferred: N/A

Non-preferred: N/A

Date of Origin: 7/29/2020

Date Last Reviewed / Revised: N/A

PRIOR AUTHORIZATION CRITERIA

(May be considered medically necessary when all of the following criteria are met)

- I. Documented diagnosis of epilepsy with seizure cluster episodes.
- II. Experiencing intermittent, stereotypic episodes of frequent seizure activity (i.e. seizure clusters, acute repetitive seizures).
- III. Currently on stable regimen of antiepileptic drug(s) (see Appendix A for examples).
- IV. Contraindication or intolerance to Diastat[®]
- V. Minimum age requirement: 6 years old.
- VI. Prescribed by or in consultation with a neurologist.

EXCLUSION CRITERIA

- Acute narrow-angle glaucoma

OTHER CRITERIA

- N/A

QUANTITY / DAYS SUPPLY RESTRICTIONS

- 5 mg, 7.5 mg, or 10 mg of diazepam in 0.1 mL nasal spray: **Up to 6 sprays** per 30 days.
 - Maximum dose: no more than 2 doses per single episode (no more than 1 episode every 5 days and 5 episodes per month)

APPROVAL LENGTH

- **Authorization:** 1 year.
- **Re-Authorization:** An updated letter of medical necessity or progress notes showing current medical necessity criteria are met and that the medication is effective.

APPENDIX

Appendix A: Antiepileptic Drugs

carbamazepine (Tegretol[®]), felbamate (Felbatol[®]), gabapentin (Neurontin[®]), lamotrigine (Lamictal[®]), levetiracetam (Keppra[®]), oxcarbazepine (Trileptal[®]), phenytoin (Dilantin[®]), phenobarbital, tiagabine (Gabitril[®]), topiramate (Topamax[®]), valproic acid (Depakene[®]), divalproex sodium (Depakote[®]), zonisamide (Zonegran[®])

REFERENCES

1. Valtoco[®] (diazepam) [package insert]. San Diego, CA: Neurelis, Inc.; January 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211635s000lbl.pdf.
2. Medispan.

DISCLAIMER: Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgement in providing the most appropriate care for their patients.